Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.4M
-
Number of holders
-
148
-
Total 13F shares, excl. options
-
61.2M
-
Shares change
-
+14.6M
-
Total reported value, excl. options
-
$971M
-
Value change
-
+$245M
-
Put/Call ratio
-
1.23
-
Number of buys
-
105
-
Number of sells
-
-39
-
Price
-
$15.88
Significant Holders of Mineralys Therapeutics, Inc. - Common Stock (MLYS) as of Q1 2025
172 filings reported holding MLYS - Mineralys Therapeutics, Inc. - Common Stock as of Q1 2025.
Mineralys Therapeutics, Inc. - Common Stock (MLYS) has 148 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61.2M shares
of 77.4M outstanding shares and own 79.05% of the company stock.
Largest 10 shareholders include Catalys Pacific, LLC (8.9M shares), RA CAPITAL MANAGEMENT, L.P. (6.15M shares), SAMSARA BIOCAPITAL, LLC (5.67M shares), SR One Capital Management, LP (3.13M shares), TCG Crossover Management, LLC (2.47M shares), BlackRock, Inc. (2.45M shares), Integral Health Asset Management, LLC (2.3M shares), Caligan Partners LP (2.15M shares), VANGUARD GROUP INC (2.04M shares), and JENNISON ASSOCIATES LLC (1.98M shares).
This table shows the top 148 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.